|Dr. Ted W. Love||Chief Exec. Officer, Pres and Director||711.88k||N/A||58|
|Dr. Charles J. Homcy M.D.||Founder, Advisor and Director||41.29k||N/A||69|
|Mr. Jeffrey S. Farrow||Chief Financial Officer||416.22k||N/A||55|
|Ms. Tricia Borga Suvari Esq.||Chief Legal Officer and Sec.||82.16k||N/A||56|
|Dr. David R. Phillips Ph.D.||Founder and Advisor||N/A||N/A||N/A|
Global Blood Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its lead product candidate is GBT440, a hemoglobin modifier that binds to hemoglobin molecules, which is in Phase 3 clinical trial for the treatment of sickle cell disease (SCD) in adult and adolescent patients, as well as evaluates the safety and pharmacokinetics of single and multiple doses of GBT440 on adolescent patients with SCD. The company is also involved in conducting Phase 2 clinical trials of GBT440 for the treatment of idiopathic pulmonary fibrosis, which is a hypoxemic pulmonary disorder; and other pre-clinical research and development activities. Global Blood Therapeutics Inc. was founded in 2011 and is headquartered in South San Francisco, California.
Global Blood Therapeutics Inc.’s ISS Governance QualityScore as of February 1, 2018 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 10.